The "Invisible Enemy" SARS-CoV-2: Viral Spread and Drug Treatment

Area of Science:

• Virology
• Infectious Diseases
• Pharmacology

Background:

• The COVID-19 pandemic, caused by SARS-CoV-2, has resulted in millions of deaths globally.
• Understanding viral transmission, symptoms, and complications is crucial for effective public health responses.

Purpose of the Study:

• To review the context of the COVID-19 pandemic, including viral spread, symptoms, and complications.
• To emphasize drug treatment strategies, particularly monoclonal antibodies, for SARS-CoV-2 infection.
• To discuss the impact of viral variants, such as Omicron, on treatment efficacy.

Main Methods:

• Review of existing medical and scientific literature on SARS-CoV-2.
• Analysis of viral characteristics, including mutations in the spike protein receptor-binding domain.
• Evaluation of in silico, in vitro, and the need for in vivo studies for drug neutralization.

Main Results:

• The Omicron variant exhibits increased infectiousness and reduced efficacy of monoclonal antibody therapy due to specific mutations.
• While numerous chemical molecules show potential for treating SARS-CoV-2, further clinical trials are necessary.
• Viral strain structure is a critical factor in determining appropriate treatment administration.

Conclusions:

• Further in vivo studies are essential to understand drug neutralization mechanisms against SARS-CoV-2.
• Extensive clinical trials are required to validate the therapeutic potential of identified chemical molecules.
• Personalized treatment strategies considering viral strain characteristics are vital for managing COVID-19.